Navigation Links
Austen BioInnovation Institute and Lubrizol Announce New Strategic Innovation Partnership
Date:12/21/2011

AKRON, Ohio, Dec. 21, 2011 /PRNewswire-USNewswire/ -- The Austen BioInnovation Institute in Akron (ABIA) and The Lubrizol Corporation in Wickliffe jointly announce today a strategic partnership to share expertise while discovering, developing and commercializing novel and emerging technologies.

The partnership combines the polymer science and clinical orthopedic and wound care expertise of ABIA with Lubrizol, a key medical polymer innovator, globally recognized as a leader in the specialty chemical industry.  Participation in the ABIA program is meant to enhance the pace of innovation across a wide range of healthcare organizations, with the potential to increase research and development funding and employment in high-tech and high-growth sectors.

The partnership will provide Lubrizol opportunities for collaborative research and product development among industry, academia, clinical care and government; the ability to pursue 'big ideas' in pre-competitive research and development; and access to materials and biomaterials expertise and resources for future applications. In return, ABIA and those in its founding member institutions will have access to the expertise of an innovative and diverse corporation that has a global footprint and a history of chemistry, engineered polymers and consumer specialty products advancements in Europe, Asia and North America.

Deb Langer, Lubrizol general manager-lifescience polymers says, "Developing this relationship with ABIA will provide Lubrizol the opportunity to better understand a patient's needs in order to design and develop effective polymer solutions."

"Partnering with Lubrizol is strategically important for the Austen BioInnovation Institute and our region," says Dr. Frank L. Douglas, ABIA President and CEO. "It provides an opportunity to not only enhance new product development efforts in biomaterial applications in orthopedics and wound care, but also allows two Ohio-based entities to add to the regional and state economic capabilities and reach."

About the Austen BioInnovation Institute in Akron
The Austen BioInnovation Institute in Akron (ABIA) – an exceptional collaboration of Akron Children's Hospital, Akron General Health System, Northeast Ohio Medical University, Summa Health System, The University of Akron and the John S. and James L. Knight Foundation – is focused on patient-centered innovation and commercialization at the intersection of biomaterials and medicine. The strategic alignment of public and private support, accompanied with Akron's rich legacy in materials science, is working to pioneer the next generation of life-enhancing and life-saving innovation that will transform Akron into a model for biomedical discovery and enterprise and move the region toward a secure economic future by accelerating the creation of more than 2,000 jobs during the next decade. For more information about ABIA, please visit www.abiakron.org.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is an innovative specialty chemical company that produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, other transportation-related fluids and industrial lubricants, as well as fuel additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for personal care products and pharmaceuticals; specialty materials, including plastics technology and performance coatings in the form of specialty resins and additives. Lubrizol's industry-leading technologies in additives, ingredients and compounds enhance the quality, performance and value of customers' products, while reducing their environmental impact.

With headquarters in Wickliffe, Ohio, The Lubrizol Corporation owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 7,000 employees worldwide. Revenues for 2010 were $5.4 billion. For more information, visit www.lubrizol.com.

Media Contacts
Lubrizol: Laura Hall, 216-447-6782, laura.hall@lubrizol.com
ABIA: Scott Rainone, 330-572-7581, srainone@abiakron.org 


'/>"/>
SOURCE Austen BioInnovation Institute in Akron
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
2. Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute
3. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
4. SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
5. Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging
6. IBM Contributes Data to the National Institutes of Health to Speed Drug Discovery and Cancer Research Innovation
7. The Food and Drug Law Institute to Present Distinguished Service and Leadership Awards to Andersen, Autor, Brady, Thirolf
8. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
9. Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies
10. Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults
11. Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
(Date:2/5/2016)... Robles, CA (PRWEB) , ... February 05, 2016 , ... When one is tired of ... be a lifesaver. There are many reasons to rent a storage unit, but before hastily ... service to many; sometimes you simply need more space. But what one is often not ...
Breaking Medicine News(10 mins):